Opportunity Information: Apply for PA 08 243
Apply for PA 08 243
- The National Institutes of Health in the education food and nutrition health sector is offering a public funding opportunity titled "Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.273 Alcohol Research Programs 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research.
- This funding opportunity was created on Oct 14, 2010 and posted on Aug 19, 2008.
- Applicants must submit their applications by Sep 7, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education.
- Other Eligible Applicants include the following Eligible Agencies of the Federal Government Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations U.S. Territory or Possession Units of Local Government
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity "Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R01)" (Funding Opportunity Number PA-08-243) is a discretionary NIH research funding announcement focused on hepatocellular carcinoma (HCC), the most common primary liver cancer. It is jointly sponsored by the National Cancer Institute (NCI), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA), reflecting the overlap between cancer biology, chronic liver disease, metabolic and digestive disorders, and alcohol-related liver injury as major contributors to HCC risk and progression. The central expectation is that proposed projects directly advance the basic biology of liver cancer and/or translate mechanistic insight into prevention, diagnostics, prognostics, or treatment strategies aimed at reducing illness and death from HCC.
The scientific scope is broad but clearly centered on mechanistic and intervention-oriented research. Applications are encouraged to investigate the causes of HCC and the underlying etiologic mechanisms, meaning studies that explain how specific exposures, injuries, infections, metabolic states, or molecular pathways drive the initiation and progression of liver tumors. A major emphasis is also placed on the development of animal models of HCC, including creation or refinement of models that better mirror human disease and can be used to test hypotheses about tumor initiation, immune interactions, fibrosis or cirrhosis-related microenvironments, and therapeutic response. In addition, the FOA invites novel approaches to prevent malignant transformation or progression, which could include strategies to interrupt carcinogenic pathways, reduce precancerous liver injury, or halt the transition from chronic liver disease to cancer. The opportunity further supports development of therapeutic or diagnostic tools, particularly those that produce reliable prognostic indicators for HCC, such as biomarkers or assay platforms that can help predict outcomes, stratify risk, or guide treatment decisions. Finally, it encourages therapeutic approaches intended to minimize morbidity and mortality in humans, which can include new treatments, combinations, delivery strategies, or biologically grounded interventions aimed at improving survival or reducing complications.
A key boundary is that the primary focus must remain on basic biology, prevention, and/or treatment of liver cancer. The FOA explicitly states that applications solely focused on population studies and epidemiology will not be supported under this announcement. In practical terms, this means proposals need to go beyond observational associations and instead deliver mechanistic insight, model development, or actionable prevention/diagnostic/therapeutic advances. Epidemiologic data might still be used as supporting context, but the core of the work needs to be laboratory, translational, or mechanistically driven rather than purely population-based.
The funding mechanism is the NIH R01, which is the standard research project grant intended for mature, hypothesis-driven studies with a well-developed research plan. This FOA is part of a set of related opportunities with the same general scientific theme but different grant mechanisms: PA-08-244 supports pilot or exploratory projects using the R21 mechanism, and PAR-08-245 supports larger, multi-project efforts using the P01 program project mechanism. Applicants are expected to choose the mechanism that fits the scale and maturity of their proposed work, with PA-08-243 serving investigators seeking full R01-level support.
Awards under this FOA are contingent on the availability of funds and on the NIH receiving a sufficient number of meritorious applications, so there is no guaranteed number of awards. The announcement lists multiple relevant NIH funding activity categories tied to cancer cause and prevention, detection and diagnosis, treatment, biology, alcohol research programs, and technological innovations to improve human health, indicating that projects can span from fundamental mechanisms to tool development and preclinical translational work as long as they remain anchored in HCC.
Eligibility is broad and includes state governments, local government units, U.S. territories or possessions, public and private institutions of higher education, nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities), for-profit organizations (including small businesses and other for-profits), and additional eligible applicants such as certain federal agencies. The FOA also allows participation by non-U.S. entities (foreign organizations) and regional organizations, which expands opportunities for international collaborations and research settings, provided the application meets NIH requirements. There is no cost sharing or matching requirement, meaning applicants are not required to provide non-federal funds as a condition of the award.
Administratively, the opportunity was posted on August 19, 2008, with an original and current closing date listed as September 7, 2011, and an archive date of October 8, 2011. The full announcement was hosted on the NIH Grants Guide, and NIH Office of Extramural Research (OER) webmaster contacts were provided for access or linking issues. Overall, the program is designed to catalyze rigorous R01-level research that clarifies how HCC arises, improves model systems for studying it, and pushes forward practical prevention, diagnostic/prognostic, and treatment advances that can ultimately reduce the burden of liver cancer.
Frequently Asked Questions (FAQs)
What is the title and funding opportunity number for this grant?
The opportunity is titled "Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R01)" and the Funding Opportunity Number is PA-08-243.
What health topic does this funding opportunity focus on?
This announcement focuses on hepatocellular carcinoma (HCC), described as the most common primary liver cancer. The goal is to support research that advances the basic biology of liver cancer and/or translates mechanistic insights into prevention, diagnostic/prognostic, or treatment strategies that reduce illness and death from HCC.
Which NIH institutes sponsor this funding opportunity?
The FOA is jointly sponsored by the National Cancer Institute (NCI), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
Why are multiple institutes involved in sponsoring this FOA?
The joint sponsorship reflects overlap among cancer biology, chronic liver disease, metabolic and digestive disorders, and alcohol-related liver injury as major contributors to HCC risk and progression.
What grant mechanism does this FOA use?
This is an NIH R01 Funding Opportunity Announcement. The R01 mechanism is the standard NIH research project grant intended for mature, hypothesis-driven studies with a well-developed research plan.
What is the overall expectation for projects submitted under this FOA?
The central expectation is that proposed projects directly advance the basic biology of liver cancer and/or translate mechanistic understanding into prevention, diagnostics/prognostics, or treatment strategies aimed at reducing morbidity and mortality from HCC.
What kinds of research topics are encouraged under this FOA?
The FOA encourages mechanistic and intervention-oriented research, including studies on the causes (etiology) of HCC, development or refinement of animal models of HCC, novel approaches to prevent malignant transformation or progression, development of diagnostic/prognostic tools (including biomarkers), and therapeutic approaches intended to minimize morbidity and mortality in humans.
Does the FOA support research on the causes (etiology) of HCC?
Yes. Applications are encouraged to investigate causes of HCC and underlying etiologic mechanisms, including how exposures, injuries, infections, metabolic states, or molecular pathways drive initiation and progression of liver tumors.
Are animal model studies specifically encouraged?
Yes. A major emphasis is the development of animal models of HCC, including creating or refining models that better mirror human disease and can be used to test hypotheses about tumor initiation, immune interactions, fibrosis or cirrhosis-related microenvironments, and therapeutic response.
What prevention research is within scope?
The FOA invites novel approaches to prevent malignant transformation or progression. Examples described include strategies to interrupt carcinogenic pathways, reduce precancerous liver injury, or halt the transition from chronic liver disease to cancer.
Does this FOA support diagnostic or prognostic tool development?
Yes. The opportunity supports development of therapeutic or diagnostic tools, particularly those producing reliable prognostic indicators for HCC, such as biomarkers or assay platforms that help predict outcomes, stratify risk, or guide treatment decisions.
What kinds of treatment research are within scope?
The FOA encourages therapeutic approaches intended to minimize morbidity and mortality in humans, including new treatments, combinations, delivery strategies, or biologically grounded interventions aimed at improving survival or reducing complications.
What is explicitly out of scope for this FOA?
The FOA explicitly states that applications solely focused on population studies and epidemiology will not be supported under this announcement.
Can epidemiologic data be included at all?
Epidemiologic data may be used as supporting context, but the core of the work must go beyond observational associations and deliver mechanistic insight, model development, or actionable prevention/diagnostic/therapeutic advances.
How broad is the scientific scope?
The scope is described as broad, but clearly centered on mechanistic and intervention-oriented research related to HCC, spanning fundamental mechanisms through tool development and preclinical translational work as long as the work remains anchored in liver cancer biology, prevention, and/or treatment.
Are awards guaranteed under this FOA?
No. Awards are contingent on the availability of funds and on NIH receiving a sufficient number of meritorious applications, and the FOA does not guarantee a specific number of awards.
What NIH funding activity categories are associated with this opportunity?
The announcement lists multiple relevant NIH funding activity categories tied to cancer cause and prevention, detection and diagnosis, treatment, biology, alcohol research programs, and technological innovations to improve human health.
Who is eligible to apply?
Eligibility is broad and includes state governments, local government units, U.S. territories or possessions, public and private institutions of higher education, nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities), for-profit organizations (including small businesses and other for-profits), and additional eligible applicants such as certain federal agencies.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The FOA allows participation by non-U.S. entities (foreign organizations) and regional organizations, provided the application meets NIH requirements.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement, meaning applicants are not required to provide non-federal funds as a condition of the award.
Are there related funding opportunities with different mechanisms?
Yes. The FOA is part of a set of related opportunities with the same general scientific theme but different mechanisms: PA-08-244 uses the R21 mechanism for pilot or exploratory projects, and PAR-08-245 uses the P01 mechanism for larger, multi-project program project efforts.
How should an applicant choose among the R01, R21, and P01 options mentioned?
Applicants are expected to choose the mechanism that fits the scale and maturity of the proposed work. PA-08-243 is positioned for investigators seeking full R01-level support for a mature, hypothesis-driven project with a well-developed plan.
When was this funding opportunity posted?
The opportunity was posted on August 19, 2008.
What are the closing and archive dates listed for this FOA?
The original and current closing date is listed as September 7, 2011, and the archive date is October 8, 2011.
Where was the full announcement hosted?
The full announcement was hosted on the NIH Grants Guide.
Who is listed for technical issues related to access or linking?
NIH Office of Extramural Research (OER) webmaster contacts were provided for access or linking issues.
What is the main boundary on the project focus?
The primary focus must remain on the basic biology, prevention, and/or treatment of liver cancer (HCC). Projects need to be mechanistically driven and/or translate mechanisms into actionable prevention, diagnostic/prognostic, or therapeutic advances rather than being purely observational population studies.
Browse more opportunities from the same category: Education Food and Nutrition Health
Next opportunity: Chronic Fatigue Syndrome Pathophysiology and Treatment (R01)
Previous opportunity: Etiology, Prevention, and Treatment of Hepatocellular Carcinoma(R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 08 243
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 08 243) also looked into and applied for these:
| Funding Opportunity |
|---|
| Lab to Marketplace Tools for Brain and Behavioral Research (SBIR R43/R44) Apply for PA 08 071 Funding Number: PA 08 071 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Lab to Marketplace Tools for Biomedical and Behavioral Research (SBIR R43/R44) Apply for PA 08 114 Funding Number: PA 08 114 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Exploratory/Developmental Clinical Research Grants in Obesity (R21) Apply for PA 09 124 Funding Number: PA 09 124 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $200,000 |
| Biobehavioral Methods to Improve Outcomes Research (R01) Apply for PA 09 125 Funding Number: PA 09 125 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Pilot and Feasibility Clinical Research Studies in Digestive Diseases and Nutrition (R21) Apply for PA 09 151 Funding Number: PA 09 151 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $200,000 |
| Development and Validation of Disease Biomarkers (R01) Apply for PA 09 204 Funding Number: PA 09 204 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Health Disparities in NIDDK Diseases (R01) Apply for PA 09 262 Funding Number: PA 09 262 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Development of Assays for High Throughput screening for use in Probe and Pre therapeutic Discovery (R01) Apply for PA 10 213 Funding Number: PA 10 213 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Health Promotion Among Racial and Ethnic Minority Males (R01) Apply for PA 10 236 Funding Number: PA 10 236 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Lab to Marketplace Tools for Brain and Behavioral Research (SBIR R43/R44) Apply for PA 11 134 Funding Number: PA 11 134 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 08 243", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.